Search This Blog

Thursday, February 13, 2025

Rogan: Elon Musk Will Relentlessly "Hunt Down" Corrupt Democrats

 by Steve Watson via Modernity.news,

Podcast king Joe Rogan had a message for Democrats, weaponised government agencies and swamp creatures alike: Elon Musk is “going to hunt you down.”

During a recent episode of his show, Rogan, who is personal friends with Elon, spoke about the continuing efforts to uncover government waste and corruption at the expense of the taxpayer through Musk’s DOGE.

Rogan specifically addressed Democrat assertions that Musk is some sort of robber baron evil billionaire after people’s social security money.

“People are worried that Elon is going to steal everyone’s money. He has $400B. Elon’s not going to steal your money. That’s not what he’s doing,” Rogan stated.

“He’s a super genius that has been f**ked with,” Rogan continued.

“When you’ve been f**ked with by these nitwits that hide behind 3-letter agencies, and you’re dealing with one of the smartest people alive helping Donald Trump get into office and find out what corruption is really going on, you f**ked up,” Rogan further warned.

He added, “You f**ked up and picked the wrong psychopath on the spectrum. He’s going to hunt you down and find out what’s going on, and that’s good for everybody.”

“That’s how you should be looking at this, like ‘Wow, we have a brilliant mind examining these really corrupt and goofy systems and bringing in a bunch of psychopath wizards,” Rogan urged, referring to the people Musk has hired to pour over government spending records.

Musk himself responded, declaring “the party is just getting started.”

The clip has been viewed over 22.5 million times at time of writing.

No wonder they’re so riled up.

Rogan’s comments come after Musk joined Trump in the Oval Office and have joint comments to the media about an executive order Trump has signed mandating federal agencies work with DOGE.

During the exchange, Musk noted “We do find it sort of rather odd that there are quite a few people in the bureaucracy who who have essentially a salary of a few hundred thousand dollars, but somehow manage to accrue tens of millions of dollars in net worth while they are in that position.”

“We’re just curious as to where it came from. Whether they have very good investing in which that case we should take their investment advice perhaps,” Musk added.

He continued, “They seem to be mysteriously getting wealthy and we don’t know why – where did it come from? I think the reality is that they are getting wealthier at the taxpayer expense.”

“There are massive amounts of blank checks that just go out…” Elon emphasised.

Musk earlier pointed to Senator Elizabeth Warren as an example of someone who has managed to accrue a net worth of $12 million, conservatively, on a $200,000 per year Senator’s salary.

President Trump has urged that there is zero chance that no kickbacks are going on and that he’s going to name names today.

*  *  *

https://www.zerohedge.com/political/rogan-elon-musk-will-relentlessly-hunt-down-corrupt-democrats

Posted by at No comments:

Wells Fargo Raises GE Healthcare Technologies Price Target

 to $103 From $96

https://www.marketscreener.com/quote/stock/GE-HEALTHCARE-TECHNOLOGIE-148175835/news/Wells-Fargo-Raises-GE-Healthcare-Technologies-Price-Target-to-103-From-96-49053460/

Posted by at No comments:

J&J progress on nipocalimab

 Johnson & Johnson (NYSE: NYSE:JNJ) has released new data on nipocalimab, an investigational drug with potential to treat diseases driven by immunoglobulin G (IgG) antibodies. Published in the peer-reviewed journal mAbs, the study presents nipocalimab's high-affinity binding to the neonatal Fc receptor (FcRn) and its capability to significantly reduce IgG levels, including harmful autoantibodies, by over 75%.

Nipocalimab is a fully human monoclonal antibody designed to selectively bind to FcRn, which plays a critical role in preserving IgG antibodies in the body. By blocking FcRn, nipocalimab aims to lower circulating IgG levels without impacting overall immune function. The drug's pH-independent binding is particularly noteworthy, as it may allow for the treatment of alloimmune diseases in pregnancy. The efficacy of nipocalimab has been supported by various preclinical studies and is consistent with outcomes from clinical trials in phases 1, 2, and 3, although its clinical significance remains to be determined.

Dr. Pushpa Narayanaswami, a neurologist at Beth Israel Deaconess Medical (TASE:PMCN) Center and Professor of Clinical Neurology at Harvard Medical School, emphasized the urgent need for targeted treatments for severe IgG-driven autoantibody diseases, such as generalized myasthenia gravis. Dr. Narayanaswami, who contributed to the research, expressed optimism about nipocalimab's unique properties in addressing these conditions' underlying causes.

Nipocalimab has received several key designations from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), including Fast Track designation for various conditions and Breakthrough Therapy designation for hemolytic disease of the fetus and newborn (HDFN) and Sjögren's disease. It has also been granted Orphan drug status for multiple diseases, reflecting its potential to address unmet medical needs.

https://www.investing.com/news/company-news/johnson--johnson-reports-progress-on-nipocalimab-93CH-3867697

Posted by at No comments:

FDA changes its mind on Astellas' geographic atrophy drug

 Astellas has shored up the competitive profile of Izervay as a treatment for eye disorder geographic atrophy (GA), getting FDA approval for an extended treatment duration.

The US regulator turned down Astellas' marketing application for the new Izervay (avacincaptad pegol) labelling last November due to a "statistical matter related to labelling language" that has now been resolved.

The new wording removes a one-year limit on the duration of treatment with the complement C5 inhibitor for GA secondary to age-related macular degeneration (AMD) – a leading cause of blindness – doing away with a restriction that has been seen as holding back its use and benefitting rival therapy Syfovre (pegcetacoplan) from Apellis.

Marci English, head of biopharma and ophthalmology development at Astellas Pharma, said the FDA's change of heart will "further [solidify] Izervay's status as a trusted choice for thousands of GA patients since its launch in 2023."

The new labelling is based on the results of the phase 3 GATHER2 trial, which showed that GA patients could get a benefit from the drug with dosing every other month, and also that there were benefits to continuing treatment out to two years.

The less frequent dosing frequency has not been included in the updated prescribing information, however. Complement C3 inhibitor Syfovre is already approved with dosing frequency of between 25 and 60 days, based on clinical trial data that also showed a benefit over two years.

The new approval is, nevertheless, good news for Astellas, which acquired Izervay as part of its $5.9 billion acquisition of the drug's developer, Iveric Bio, in 2023. Efforts to bring the drug to market elsewhere have run into trouble, however, and Astellas withdrew a marketing application for Izervay in the EU last October after getting feedback on its application from the EMA.

It was filed for approval in Japan earlier this month, and Astellas is considering submitting Izervay in selected EU markets, rather than going down the EU-wide regulatory route.

Izervay and Syfovre are addressing a potentially enormous market, leading analysts to previously predict blockbuster sales levels for both drugs, although, Apellis' drug has been linked to side effects that have trimmed back some of the more optimistic forecasts.

Astellas reported sales of Izervay rocketed to JPY 44.4 billion (around $289 million) in the first nine months of its current fiscal year – a near-ninefold increase on the same year-earlier period – although it still recorded a charge of JPY 115 billion linked to delays for the programme in ex-US markets.

For comparison, Apellis recorded Syfovre sales of around $445 million in the first nine months of calendar 2024, with recent turnover showing signs of plateauing.

GA affects an estimated 1.5 million people in the US, but approximately three-quarters of people living with the condition are thought to be undiagnosed. Without treatment, an estimated 66% of people with GA may become blind or severely visually impaired.

https://pharmaphorum.com/news/fda-changes-its-mind-astellas-geographic-atrophy-drug

Posted by at No comments:

Sanofi Hit With $250M Impairment After Scrapping J&J-Partnered E. coli Vaccine

 

Without providing specific data, Sanofi on Thursday announced that the experimental vaccine did not significantly prevent invasive E. coli disease versus placebo.

Sanofi and Johnson & Johnson on Thursday terminated the Phase III E.mbrace study of their investigational vaccine for invasive E. coli disease due to disappointing data.

As a result of the termination, Sanofi will record a $250 million impairment charge, to be reflected in its fourth-quarter 2024 balance sheet, according to the company’s press announcement.

The decision to discontinue E.mbrace came after an independent data monitoring committee found during a scheduled review of the trial that the vaccine candidate “was not sufficiently effective at preventing” the disease versus placebo. Safety was clean overall, with no signals of concern linked to the shot throughout the study.

Patients who developed invasive E. coli disease (IED) were given adequate treatment, according to Thursday’s announcement.

Jean-François Toussaint, global head of vaccines R&D at Sanofi, said in a statement that the vaccine candidate “was not associated with sufficient efficacy to support the trial continuation” and that the pharma was “disappointed” by these findings. Sanofi will “work tirelessly” to understand the reasons behind the failure, which it plans to share with the broader medical community “once available,” Toussaint added.

Sanofi and J&J, through the latter’s subsidiary Janssen Pharmaceuticals, inked their vaccine pact in October 2023, with Sanofi surrendering $175 million upfront—though according to Thursday’s announcement, the pharma has already made $250 million in total payments under this deal, including certain milestones.

The partners set their sights on IED, which occurs when bacteria that typically stay in the intestines infiltrate and infect other parts of the body. Patients with IED suffer from a wide variety of infections, some of which can become severe and life-threatening, especially for seniors. To combat IED and its related complications, Sanofi and J&J agreed to co-fund R&D activities related to the vaccine candidate.

Following Thursday’s discontinuation, Janssen, the study sponsor, will be responsible for continuing the appropriate safety follow-up for enrolled participants.

Sanofi’s E. coli stumble comes just days after another big-ticket partnership suffered some strain. Last week, Dupixent partner Regeneron sued Sanofi, alleging that it failed to provide “full access to material information” regarding sales of the blockbuster drug, and that Sanofi, when asked to hand over relevant figures, “stonewalled” Regeneron.

For J&J, the discontinuation follows its massive $14.6 billion acquisition of neuro specialist Intra-Cellular last month. In the pharma’s fourth-quarter and full-year business report a week later, CEO Joaquin Duato told investors on a call that the pharma will be focusing on “smaller opportunities” for the rest of the year.

https://www.biospace.com/drug-development/sanofi-hit-with-250m-impairment-after-scrapping-j-j-partnered-e-coli-vaccine

Posted by at No comments:

West Pharma Guidance Dissaapoints

 Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 2.3% year on year to $748.8 million. On the other hand, the company’s full-year revenue guidance of $2.89 billion at the midpoint came in 5% below analysts’ estimates. Its non-GAAP profit of $1.82 per share was 5.3% above analysts’ consensus estimates.

https://finance.yahoo.com/news/west-pharmaceutical-services-nyse-wst-110535763.html

Posted by at No comments:

Moleculin Positive FDA Guidance to Speed Registration Trial in Acute Myeloid Leukemia

 Company remains on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) in the first quarter of 2025

https://www.prnewswire.com/news-releases/moleculin-receives-positive-fda-guidance-for-acceleration-of-its-registration-enabling-miracle-trial-for-rr-acute-myeloid-leukemia-aml-302375907.html

Posted by at No comments:
Subscribe to: Posts (Atom)